We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Figure 4

Figure 4. From: RAPID RESPONSE TO FLUOXETINE IN WOMEN WITH PREMENSTRUAL DYSPHORIC DISORDER.

Examples of symptom remission (i.e. switch-out) characteristics after SRI treatment in three separate patients: (1) a gradual remission of symptoms over 5 to 6 days, (2) moderately rapid symptom remission over 2 to 3 days, and (3) a switch-out of the symptomatic state within 24 hr.

Emma M. Steinberg, et al. Depress Anxiety. 2012 June;29(6):531-540.
2.
Figure 1

Figure 1. From: RAPID RESPONSE TO FLUOXETINE IN WOMEN WITH PREMENSTRUAL DYSPHORIC DISORDER.

Scores on the rating scale for PMTS (mean + SEM) were significantly improved compared with baseline on the second day after the start of SRI treatment (Day 1). Improvement was maintained until menses (ANOVA-R: F4,40 = 9.1, P = .001; Bonferroni t ≤ 3.8, df = 40, P ≤ .01). Seven of 12 women experienced a 50% reduction relative to baseline within 2 days of treatment.

Emma M. Steinberg, et al. Depress Anxiety. 2012 June;29(6):531-540.
3.
Figure 2

Figure 2. From: RAPID RESPONSE TO FLUOXETINE IN WOMEN WITH PREMENSTRUAL DYSPHORIC DISORDER.

Hourly VAS ratings of sadness and irritability for 10 hr each day prior to and after the start of treatment with fluoxetine 20 mg daily on the morning of Day 1 (mean + SEM). Ratings on the VAS scales showed a significant improvement after SRI in the symptoms of irritability, as well as anxiety, sadness, and mood swings after the start of treatment that did not differ across individual symptoms. (ANOVA-R: main effect of symptom type F3,30 = 0.9, P = NS, symptom × day interaction F15,150 = 1.8, P = .2), symptom × day ×hour interaction F135,1350 = 1.0, P = .5). There also was significant improvement in the symptom severity from the first to the last ratings of the day regardless of symptom or day of treatment.

Emma M. Steinberg, et al. Depress Anxiety. 2012 June;29(6):531-540.
4.
Figure 3

Figure 3. From: RAPID RESPONSE TO FLUOXETINE IN WOMEN WITH PREMENSTRUAL DYSPHORIC DISORDER.

Three-point moving averages of the hourly VAS rating of irritability in women with PMDD who were treated with fluoxetine during the luteal phase, and women with PMDD who received no treatment. Ratings in women receiving fluoxetine represent pretreatment ratings (Day −2, −1) and after receiving fluoxetine 20 mg daily in morning on Day 1, whereas ratings in untreated women represent ratings premenses (Day −2, −1) and after the onset of menses (Day 1). The onset of menses and the initiation of SRI treatment were accompanied by similar patterns of symptom response (ANOVA-R of the ratings for all four symptoms during Day 1–3 demonstrated an identical pattern of symptom improvement with significant effects of both day and hour that reflected an improvement in scores of all four symptoms after the onset of either SRI treatment or menses (main effect of day F2,32 = 8.3, P = .003; main effect of hour F9,144 = 5.9, P < .001).

Emma M. Steinberg, et al. Depress Anxiety. 2012 June;29(6):531-540.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk